It's not about following. Only curious as to how you arrived at the number.
Was hoping to gain some insight on what catalysts you think would bring us to that SP.
As Biotech mentioned previously, it won't be sales figures. Even if ENDV get sales going fast with the distribution channels, those numbers will be seen 1Q 2019.
The kidney news might help, but we really need to see the human clinicals begin.
A liver preclinical success story has the potential to be huge if significant enough. ENDV has been tinkering with it for a long time though, so my hopes for that are low. Must not be as easy as hoped for.
ENDV could start human clinicals on concussion and MS later this year. Still waiting on the redesign of the technology/ garments/attachments.
Hope and expectations have not been very successful in elevating the SP here.
The market wants to see results and action.
News 
Market Data 
Discover 
AI
